Dyne Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing is an annual report; it does not provide a clear standalone fourth-quarter financial breakdown. Dyne is a pre-revenue biotechnology company developing muscle-disease therapeutics using its FORCE platform.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $121.3 million | $45.2 million |
| General and administrative expense | $28.7 million | $13.4 million |
| Total operating expenses | $150.0 million | $58.6 million |
| Net loss | $149.3 million | $59.4 million |
| Net loss per share, basic and diluted | $2.93 | $4.13 |
| Net cash used in operating activities | $119.6 million | $46.5 million |
| Net cash used in investing activities | $137.9 million | $45.7 million |
| Net cash provided by financing activities | $157.8 million | $380.7 million |
- At year-end, cash and cash equivalents were $200.8 million and marketable securities were $175.7 million, totaling $376.6 million in cash, cash equivalents and marketable securities.
- Current assets were $382.4 million; current liabilities were $28.7 million. Total assets were $425.7 million and total liabilities were $57.5 million.
- The company reported no outstanding borrowings at year-end; its $10.0 million term loan was repaid in October 2020. Lease liabilities totaled $32.6 million at December 31, 2021.
- Accumulated deficit was $228.5 million. No income tax benefit was recorded; the company maintained a full valuation allowance against deferred tax assets.
Material changes versus FY2020
- Net loss increased by $89.9 million, while total operating expenses rose by $91.4 million. R&D expense increased $76.1 million, principally reflecting higher external manufacturing and research costs, expanded research activity, and IND-enabling work. G&A increased $15.3 million, including higher personnel, stock-based compensation, and public-company costs.
- Operating cash use increased by $73.1 million. The company raised $157.2 million net in a January 2021 follow-on offering; FY2020 financing had included IPO and preferred-stock proceeds.
- Marketable securities increased to $175.7 million from $44.5 million. The company began recognizing operating lease right-of-use assets and liabilities in 2021 and reported $36.3 million of right-of-use assets.
Outlook, programs and risks
- Management estimated existing cash, cash equivalents and marketable securities would fund operating expenses and capital needs into the second half of 2024, subject to assumptions and potential changes in the operating plan. It expected liquidity to support IND submissions for its lead programs and proof-of-concept readouts in multiple programs.
- Management planned multiple-country regulatory filings for DYNE-101 (DM1) in Q2 2022 and, subject to regulatory clearance, a global multiple-ascending-dose trial beginning in mid-2022. DYNE-301 (FSHD) IND submission was anticipated in the second half of 2022.
- The FDA placed the DYNE-251 (DMD, exon 51) IND on clinical hold and requested additional clinical and nonclinical information. Dyne expected to respond in Q2 2022 and planned a mid-2022 trial start only if the FDA was satisfied. The company had not advanced any product candidate into clinical trials as of the filing’s reporting period.
- Preclinical findings for the programs and FORCE platform are not proof of safety or efficacy in people. Management emphasized substantial development, regulatory and manufacturing uncertainty; no product has been approved or generated revenue, and significant losses are expected to continue.
- Key risks include clinical-hold delays, failure of preclinical results to translate, clinical-trial enrollment and safety challenges, reliance on third-party manufacturers and suppliers, competition, intellectual-property and licensing risks, and potential COVID-19 effects on research, trials and supply chains. The company also stated it had not experienced material business disruptions from COVID-19 to date.
- Dyne had a $400 million universal shelf registration and a $150 million at-the-market sales agreement; no shares had been sold under the ATM program as of the filing. Additional financing may dilute shareholders or require less favorable partnerships or licensing.
- Management reported disclosure controls and internal control over financial reporting were effective at December 31, 2021. The independent auditor issued an unqualified opinion on the financial statements but did not attest to internal control effectiveness.
Important facts for investors to verify
- Whether the FDA lifted the DYNE-251 clinical hold, what additional information it required, and how that affected trial timing.
- Whether DYNE-101 and DYNE-301 filings and planned clinical milestones occurred, and whether human data support the preclinical claims.
- Cash burn, investment balances, financing needs and whether the stated runway into the second half of 2024 remains achievable.
- Manufacturing capacity, supplier redundancy and any material changes to clinical supply or development costs.
- Progress and scope of patent protection, third-party licensing obligations, and competitive developments in DM1, DMD and FSHD.